Vimarsana
Biggest News Aggregation in the World

Page 3 - Life Sciences Division News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Life Sciences Division. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Life Sciences Division Today - Breaking & Trending Today

Kenco Partners with QPharma to Optimize Drug Sampling Distribution & Compliance - Vimarsana News

Kenco Partners with QPharma to Optimize Drug Sampling Distribution & Compliance

3PL and cloud-based compliance solutions provider will ensure enhanced fulfillment and alignment with regulations for pharmaceutical companies

How Can Broken DNA Be Repaired In Space? - Vimarsana News

How Can Broken DNA Be Repaired In Space?

There are a number of things which can damage DNA - toxic chemicals are the primary concern on earth but, in space, ionized radiation is the worry. Unrepaired DNA can lead to mutations, which in turn can lead to diseases like cancer.

NeoGenomics Announces Senior Leadership Promotions - Vimarsana News

NeoGenomics Announces Senior Leadership Promotions

NeoGenomics, Inc. , a leading oncology testing services company, today announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted to Chief...

NeoGenomics, Inc. Announces Senior Leadership Promotions - Vimarsana News

NeoGenomics, Inc. Announces Senior Leadership Promotions

NeoGenomics, Inc. announced two promotions within its senior leadership team, effective immediately. Warren Stone has been promoted to Chief Commercial Officer and will lead NeoGenomics? clinical and...

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 - Vimarsana News

Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of...